Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up
- 30 November 2011
- journal article
- research article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 12 (12), 1101-1108
- https://doi.org/10.1016/s1470-2045(11)70270-4
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Long-Term Follow-Up of Women in Trials of Adjuvant Therapy for Breast Cancer: Is It Still Important?Journal of Clinical Oncology, 2011
- Analyses Adjusting for Selective Crossover Show Improved Overall Survival With Adjuvant Letrozole Compared With Tamoxifen in the BIG 1-98 StudyJournal of Clinical Oncology, 2011
- American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast CancerJournal of Clinical Oncology, 2010
- Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus TamoxifenJournal of Clinical Oncology, 2010
- Letrozole Therapy Alone or in Sequence with Tamoxifen in Women with Breast CancerThe New England Journal of Medicine, 2009
- Design, conduct, and analyses of Breast International Group (BIG) 1-98: A randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancerClinical Trials, 2009
- Proposal for Standardized Definitions for Efficacy End Points in Adjuvant Breast Cancer Trials: The STEEP SystemJournal of Clinical Oncology, 2007
- Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98Journal of Clinical Oncology, 2007
- A Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast CancerThe New England Journal of Medicine, 2005
- Annual hazard rates of recurrence for breast cancer after primary therapy.Journal of Clinical Oncology, 1996